Home/Pipeline/VV116 Dry Suspension

VV116 Dry Suspension

Respiratory Syncytial Virus (RSV) Infection

Phase 2Completed; Breakthrough Therapy Designation in China

Key Facts

Indication

Respiratory Syncytial Virus (RSV) Infection

Phase

Phase 2

Status

Completed; Breakthrough Therapy Designation in China

Company

Vigonvita

About Vigonvita

A Chinese biopharma company with a fully integrated platform developing and commercializing drugs for viral infections, neuropsychiatry, and reproductive health.

View full company profile

Therapeutic Areas

Infectious Disease Neurology Psychiatry Urology/Reproductive Health

Other Respiratory Syncytial Virus (RSV) Infection Drugs

Drug	Company	Phase	Status
CUR-N399	Curovir	Pre-clinical	Active
Alfacyte	ILC Therapeutics	Pre-clinical	Active
Zelicapavir (EDP-938)	Enanta Pharmaceuticals	Phase 2b	Active